News

Filter

Current filters:

XareltoOncology

1 to 9 of 11 results

Bayer initiates Ph III trail of Xarelto in cardiac event prevention; R&D day presentation

14-11-2012

German drug major Bayer (BAYN: DE) has initiated the Phase III COMPASS study of its oral anticoagulant…

AlpharadinBayerCardio-vascularOncologyOphthalmicsPharmaceuticalResearchStivargaXarelto

Roche returns rights to TB-403 to ThromboGenics and BioInvent, who abandon TB-402 development

05-06-2012

Belgium-based biopharma company ThromboGenics NV (Euronext Brussels: THR) and co-development partner…

BayerBioInventBiotechnologyLicensingOncologyOphthalmicsPharmaceuticalRocheTB-402TB-403ThromboGenicsXarelto

NICE recommendations on Bayer's Xarelto and Amgen Xgeva's for UK NHS use

30-03-2012

Following the receipt of further evidence from Bayer HealthCare, a unit of German drugmaker Bayer (BAY:…

AmgenBayerCardio-vascularEuropeOncologyPharmaceuticalPricingRegulationXareltoXgeva

Bayer and Algeta’s Alpharadin efficacy confirmed; Almirall to market Xarelto in Spain

13-02-2012

German drug major Bayer (BAY: DE) and Norwegian partner Algeta (OSE: ALGETA) announced that the survival…

AlgetaAlmirallAlpharadinBayerCardio-vascularEuropeMarkets & MarketingOncologyPharmaceuticalRegulationResearchXarelto

Bayer’s Xarelto OKed in Japan; promising regorafenib data

19-01-2012

Bayer Healthcare, a unit of Germany’s Bayer AG (BAY: DE), had a couple of good news item to report…

BayerCardio-vascularOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationResearchXarelto

Janssen files Xarelto sNDA for ACS; FDA to review Amgen’s Xgeva for CRPC

30-12-2011

US health care giant Johnson & Johnson’s (NYSE: JNJ) Janssen Research & Development, has submitted…

AmgenBayerBiotechnologyCardio-vascularJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationXareltoXgeva

Bayer boasts four potential pipeline blockbusters

21-12-2011

German drugs and crop and material sciences group Bayer (BAT: DE) said yesterday that it plans to continue…

AlpharadinBayerCardio-vascularEyleaFinancialMarkets & MarketingOncologyOphthalmicsPharmaceuticalregorafenibResearchXarelto

1 to 9 of 11 results

COMPANY SPOTLIGHT

Menarini

Back to top